CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Near Add Your Location

Sorting 15 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Roswell Park Cancer Institute
Buffalo, NY
  • Accepting patients
  • Show Principal Investigator
University of Nebraska Medical Center
Fred & Pamela Buffett Cancer Center
Omaha, NE
  • Accepting patients
  • Show Principal Investigator
Mayo Clinic (Arizona)
Phoenix, AZ
  • Accepting patients
  • Show Principal Investigator
Mayo Clinic (Rochester)
Rochester, MN
  • Accepting patients
  • Show Principal Investigator
Mayo Clinic (Jacksonville)
Jacksonville, FL
  • Accepting patients
  • Show Principal Investigator
Northside Hospital (Atlanta)
Atlanta, GA
  • Accepting patients
  • Show Principal Investigator
Dana-Farber Cancer Institute
Boston, MA
  • Accepting patients
  • Show Principal Investigator
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
  • Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 354-2873

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.